AMEBA Amoeba SA

Edison issues report on Amoéba (ALMIB)

Edison Investment Research Limited
Edison issues report on Amoéba (ALMIB)

21-Jun-2024 / 12:36 GMT/BST
The issuer is solely responsible for the content of this announcement.


 

London, UK, 21 Juni 2024

 

Edison issues report on Amoéba (ALMIB)

to view the full report.

All reports published by Edison are available to download free of charge from its website

Edison is authorised and regulated by the .

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

+44 (0)20 3077 5700

Connect with Edison on:

 

LinkedIn 

X  

YouTube 



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1930811  21-Jun-2024 

fncls.ssp?fn=show_t_gif&application_id=1930811&application_name=news&site_id=research_pool~~~9efe1c65-8ece-4ff7-9608-f21c8e0a38a3
EN
21/06/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amoeba SA

 PRESS RELEASE

Edison issues report on Amoéba (ALMIB)

Edison Investment Research Limited Edison issues report on Amoéba (ALMIB) 21-Jun-2024 / 12:36 GMT/BST The issuer is solely responsible for the content of this announcement.   London, UK, 21 Juni 2024   Edison issues report on Amoéba (ALMIB) to view the full report. All reports published by Edison are available to download free of charge from its website Edison is authorised and regulated by the . Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities. For more information, p...

Toby Thorrington
  • Toby Thorrington

Amoeba - Focused on high-value opportunities

Amoéba has achieved promising results for the use of its amoeba-based active ingredient in skincare cosmetics in a series of lab and human volunteer trials. In addition, the company secured regulatory approval in the United States and a recommendation for approval in the European Union in 2022 for the active ingredient used in its innovative biological fungicides. Since then, it has tested this active ingredient in standalone and blended use and hopes to achieve product approvals by H125. Amoéba...

Toby Thorrington
  • Toby Thorrington

Amoeba - Biocontrol plant paves path to commercialisation

Thus far, FY23 has marked a year of successful advancement for Amoéba: (1) the development of its biocontrol plant is ongoing, poised to achieve production of 40 tonnes per annum of W. magna lysate; (2) a third scientific article has been published, which highlights the efficacy of its biocontrol product; and (3) the company has announced a potential further application for W. magna lysate in cosmetic skincare. The new application will not hinder advancement of the biological fungicide product. ...

Arnaud Despre ... (+9)
  • Arnaud Despre
  • Augustin Socié
  • Clément Bassat
  • Gaetan Calabro
  • Jeremy Sallee
  • Maxence Dhoury
  • Mohamed Kaabouni
  • Nicolas Delmas
  • Nicolas Royot
IPS IPSOS
ALHRG HERIGE ... (+21)

La Matinale - 22-06-2023

LA VALEUR DU JOUR : ACTIA GROUP : Feedback Conférence Portzamparc – Conserver (3), obj. 4.70€ Cours: 4.67€ au 21/06/23 AFYREN : Feedback Conférence Portzamparc – Acheter (1), obj. 9.40€ Cours: 5.70€ au 21/06/23 AMOEBA : Feedback Conférence Portzamparc – Acheter (1), obj. 0.72€ Cours: 0.58€ au 21/06/23 BENETEAU : Feedback Conférence Portzamparc – Acheter (1), obj. 23.0€ Cours: 15.3€ au 21/06/23 EXAIL TECHNOLOGIES : Feedback Conférence Portzamparc – Acheter (1), obj. 26.5€ Cours: 20.2€ au 21/...

Toby Thorrington
  • Toby Thorrington

Amoeba - Scaling up for commercialisation

Following on from the press release in March that provided preliminary data on the FY22 results, Amoéba has published its FY22 universal registration document, which contains detailed financial information for the year. We leave our FY23 estimates unchanged.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch